PepGen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

PepGenDer Gewinn des Unternehmens wird voraussichtlich um 1.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 77.7% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 9% pro Jahr wachsen.

Wichtige Informationen

-1.8%

Wachstumsrate der Gewinne

9.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	77.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Nov 19

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Aug 06

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Jul 31

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Sep 07

PepGen GAAP EPS of -$1.23 misses by $0.47

Aug 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PEPG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-113	-129	-147	3
12/31/2025	N/A	-113	-116	-125	4
12/31/2024	N/A	-95	-95	-89	4
9/30/2024	N/A	-87	-83	-82	N/A
6/30/2024	N/A	-89	-75	-75	N/A
3/31/2024	N/A	-80	-78	-76	N/A
12/31/2023	N/A	-79	-72	-69	N/A
9/30/2023	N/A	-74	-66	-63	N/A
6/30/2023	N/A	-69	-71	-67	N/A
3/31/2023	N/A	-67	-66	-62	N/A
12/31/2022	N/A	-69	-63	-59	N/A
9/30/2022	N/A	-61	-55	-52	N/A
6/30/2022	N/A	-51	-41	-39	N/A
3/31/2022	N/A	-39	-34	-32	N/A
12/31/2021	N/A	-27	-23	-23	N/A
9/30/2021	N/A	-23	-17	-17	N/A
6/30/2021	N/A	-15	-10	-10	N/A
3/31/2021	N/A	-10	-4	-4	N/A
12/31/2020	N/A	-4	-2	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PEPG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: PEPG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: PEPG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: PEPG wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: PEPG wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PEPG in 3 Jahren voraussichtlich hoch sein wird

PepGen Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 13% to US$17.00

Price target decreased by 9.3% to US$19.60

Price target decreased by 14% to US$20.00

Recent updates

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Price target decreased by 13% to US$17.00

New major risk - Revenue and earnings growth

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Pepgen Announces First Patient Dosed in Phase 1 Freedom-Dm1 Clinical Trial of Pgn-Edodm1 for Myotonic Dystrophy Type 1

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability

New major risk - Revenue and earnings growth

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

New major risk - Share price stability

Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Key Executive notifies of intention to sell stock

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

PepGen Inc. Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies

High number of new and inexperienced directors

PepGen Inc. Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates

PepGen Inc. Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Appoints Habib Dable to Board of Directors

Here's Why We're Not Too Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

PepGen GAAP EPS of -$1.23 misses by $0.47

PepGen Inc. Appoints Caroline Godfrey to Its Scientific Advisory Board

PepGen Inc. has completed an IPO in the amount of $108 million.

High number of new and inexperienced directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken